Recent Updates
Recently added Catalysts

taranabant

Phase 2

Smoking | Small molecule | Other |Merck & Company, Inc.|Last Updated: Sep 25, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLEDBiomarker
Total Trials1
Total Enrollment300
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00109135A Study to Investigate a Research Drug as an Aid for Smoking Cessation in Chronic Cigarette Smokers (0364-007)PHASE2 COMPLETED 300Jan 1, 2005Jun 1, 2005Sep 25, 2015 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Quitting smoking after 8 weeks of treatment by measuring lab values and expired breath CO levels
after 8 weeks of treatment
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
taranabantDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersYes

Inclusion Criteria: * Smoking greater than/equal to 10 cigarettes/day for at least 1 year * Laboratory tests that meet the criteria of the study * In overall good health as determined by the investigator Exclusion Criteria: * Psychiatric diagnoses * Certain cancers * Patients who use nicotine rep...

Unlock Eligibility Criteria